{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T19:29:57Z","timestamp":1707161397488},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.transproceed.2008.05.030","type":"journal-article","created":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T09:13:21Z","timestamp":1217582001000},"page":"2070-2072","source":"Crossref","is-referenced-by-count":4,"title":["Activated Recombinant Protein C in Septic Shock Early After Liver Transplantation: A Case Report"],"prefix":"10.1016","volume":"40","author":[{"given":"P.","family":"Feltracco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bortolato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Furnari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Milevoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2008.05.030_bib1","first-page":"101","article-title":"The definition of septic shock: implications for treatment","volume":"9","author":"Marik","year":"2007","journal-title":"Crit Care Resusc"},{"key":"10.1016\/j.transproceed.2008.05.030_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/01.CCM.0000117317.18092.E4","article-title":"Surviving sepsis campaign guidelines for management of severe sepsis and septic shock","volume":"32","author":"Dellinger","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.transproceed.2008.05.030_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/01.TP.0000054842.34916.E8","article-title":"Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis","volume":"75","author":"Kulkarni","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2008.05.030_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Eng J Med"},{"key":"10.1016\/j.transproceed.2008.05.030_bib5","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJMe058160","article-title":"Severe sepsis and therapy with activated Protein C","volume":"353","author":"Parrillo","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2008.05.030_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2044.2007.04952.x","article-title":"The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant","volume":"62","author":"Browne","year":"2007","journal-title":"Anaesthesia"},{"key":"10.1016\/j.transproceed.2008.05.030_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/glycob\/4.2.221","article-title":"Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide","volume":"4","author":"Grinnel","year":"1994","journal-title":"Glycobiology"},{"key":"10.1016\/j.transproceed.2008.05.030_bib8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/01.CCM.0000120058.88975.42","article-title":"Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia","volume":"32","author":"Hoffman","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.transproceed.2008.05.030_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1185\/030079906X162737","article-title":"Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs","volume":"23","author":"Ernst","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.transproceed.2008.05.030_bib10","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1097\/01.CCM.0000181729.46010.83","article-title":"DRotregogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment","volume":"33","author":"Vincent","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.transproceed.2008.05.030_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2165\/00002018-200730110-00002","article-title":"Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis","volume":"30","author":"De Backer","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.transproceed.2008.05.030_bib12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.amjsurg.2004.06.008","article-title":"Benefit\/risk profile od drotrecogin alfa (activated) in surgical patients with severe sepsis","volume":"188","author":"Barie","year":"2004","journal-title":"Am J Surg"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134508006131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134508006131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T20:25:12Z","timestamp":1545855912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134508006131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0041134508006131"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2008.05.030","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}